Jami A. Fukui, MD
This email address is being protected from spambots. You need JavaScript enabled to view it. | (808) 441-8199
Full Member, Cancer Biology, University of Hawaiʻi Cancer Center
Core Clinical Member, Translational and Clinical Research, University of Hawaiʻi Cancer Center
Academic Appointment(s):
Associate Professor (Associate Researcher), University of Hawaiʻi Cancer Center, University of Hawaiʻi at Mānoa
Assistant Professor, Department of Medicine, John A. Burns School of Medicine, University of Hawaiʻi at Mānoa
Degree(s):
MD, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ
Internal Medicine Residency, Mount Sinai Hospital, New York, NY
Hematology/Oncology Fellowship, Mount Sinai Hospital, New York, NY
Honors
NCI Breast Cancer Steering Committee member the National Cancer Institute (NCI) Community Oncology Research Program (NCORP) representative
Southwest Oncology Group (SWOG) Supportive Oncology Committee Member
Research Focus
Dr. Fukui is an Associate Professor at the University of Hawaiʻi Cancer Center. Her interests are in breast cancer clinical and translational research, developing clinical trial protocols, and providing cancer care to residents of Hawaiʻi.
- Tumor microenvironment
Characterizing the tumor microenvironment (TME) has led to novel therapies in cancer treatment. Within the TME, tumor infiltrating lymphocytes are both predictive of therapy response and prognostic in breast cancer. Evaluating these immune cells can inform clinicians and their patients of potential therapy options and overall outcomes. - Racial/ethnic disparities in breast cancer treatment and outcomes
Hawaiʻi has one of the highest incidence of breast cancer cases in the U.S. There are accompanying differences in breast cancer mortality according to racial/ethnic group. Evaluating disparities in cancer treatment and coordinating quality improvement for breast cancer care within Hawaii can be achieved through clinical trials. - Lifestyle modification and symptom control in cancer survivors.
The role of lifestyle modification for prevention of primary breast cancer, secondary cancers and recurrence is an important adjunct to cancer care. Symptom control in cancer patients and survivors can improve therapy adherence and overall quality of life. Clinical trials with patient reported outcomes are increasingly important to capture multiple aspects of patient care.
Selected Publications
Sasaki T, Liyanage A, Bansil S, Silva A, Pagano I, Hidalgo EY, Jones C, Ueno NT, Takahashi Y, Fukui J. (2024). Differences in Breast Cancer Subtypes among Racial/Ethnic Groups. Cancers (Basel). 2024 Oct 12;16(20):3462. doi: 10.3390/cancers16203462.
Bansil S, Silva A, Taniguchi A, Wiedmer C, Fernandez M, Pagano I, Vierkoetter K, Killeen J, Fukui J. (2023). Racial/Ethnic Differences Among Tumor-Infiltrating Lymphocytes in Breast Cancer Tumors. Oncologist; Feb 8;28(2):116-122. doi: 10.1093/oncolo/oyac239. PMID: 36495151.
Fukui J, White K, Frankland TB, Oshiro C, Wilkens L. (2021). Weight changes according to treatment in a diverse cohort of breast cancer patients. BMC Cancer; 21:1005.
Publication list via PubMed
Active Grants
J. Fukui, PI
Robert A. Winn Excellence in Clinical Trials Award Program-Career Development Award
"Overcoming Barriers to Enhance Breast Cancer Screening Rates among Native Hawaiian and Other Pacific Islander Women"
10/2024 – 09/2026
J. Fukui, Co-Investigator J. Shepherd
L. LeMarchand and J. Berenberg (PIs)
NCI P20CA275734
"Hawaii Minority Health and Cancer Disparities SPORE-project 3"
We will address the very high breast cancer burden of Native Hawaiians and the rising rates in Asian Americans by testing the adequacy of current radiomic risk prediction algorithms for predicting breast cancer in these populations and by investigating related molecular and histopathologic features of breast tumor environment which may be related to visceral adiposity and have prognostic significance.
09/2023 – 07/2026
